Study on the Application of Bupivacaine Liposome Injection in the Fast Track Recovery after Open Ovarian Cancer Surgery

Study on the Application of Bupivacaine Liposome Injection in the Fast Track Recovery after Open Ovarian Cancer Surgery - Study on the Application of Bupivacaine Liposome Injection in the Fast Track Recovery after Open Ovarian Cancer Surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400083026

Enrollment

Unknown

Registered

2024-04-15

Start date

2024-04-30

Completion date

Unknown

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Interventions

Bupivacaine Liposomal Group (Group A):After induction and intubation with a standardized anesthesia protocol, 266mg of bupivacaine liposome (maximum single dose for analgesia as recommended by the dru

Ropivacaine Group (Group B):After induction and intubation with a standardized anesthesia protocol, 200mg of ropivacaine injection (maximum single dose for analgesia as recommended by the drug instruc

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The provided information outlines the inclusion criteria for a clinical study involving 60 patients undergoing open surgery for ovarian cancer: Age criteria: Patients must be =18 years and =80 years old. Surgical procedure: The surgery must be an open surgery for ovarian cancer. ASA classification: Patients should be classified as ASA (American Society of Anesthesiologists) physical status Class II to III. Informed consent: Patients must provide informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: A. Contraindications for nerve block: Infection at the site of puncture, allergy to local anesthetics, coagulation dysfunction. B. Liver and kidney function failure. C. Use of analgesic drugs before surgery. D. History of chronic pain or opioid abuse. E. Mental illness. F. Pregnant women, breastfeeding women. G. Patients who refuse to participate. H. Other individuals unsuitable for clinical trials. I. Patients undergoing repeat laparotomy.

Design outcomes

Primary

Measure	Time frame
systolic pressure;diastolic pressure;mean arterial pressure;heart rate;Dosage of propofol used;Dosage of sufentanil used;Remifentanil usage;The usage of Shunatracurium;Dosage of vasoactive drugs used;Additional analgesic dosage during PACU;Removal time of tracheal catheter;PACU stay time;Dynamic and static VAS ,NRS ratings;Hospitalization time;	—

Secondary

Measure	Time frame
Postoperative use of sufentanil;PCA self-control frequency and total dosage of medication;Remedial analgesic medication time and dosage;Drainage tube removal time;First time getting out of bed activity time;Postoperative dizziness and frequency of postoperative nausea and vomiting;WBC and TNF on the first day of hospitalization- a IL-6 and CRP levels;WBC and TNF on the first day after surgery- a IL-6 and CRP levels;	—

Measure

Time frame

Postoperative use of sufentanil;PCA self-control frequency and total dosage of medication;Remedial analgesic medication time and dosage;Drainage tube removal time;First time getting out of bed activity time;Postoperative dizziness and frequency of postoperative nausea and vomiting;WBC and TNF on the first day of hospitalization- a IL-6 and CRP levels;WBC and TNF on the first day after surgery- a IL-6 and CRP levels;

—

Countries

China

Contacts

Public ContactGang Yao

Liuzhou Workers' Hospital

YaoGang298@outlook.com+86 152 7708 0060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026